UNASSIGNED: The VP8*-rotavirus+AAY+HAV-VP1 fusion protein was produced using an Escherichia coli expression system. The recombinant protein had a molecular weight of approximately 45.5 kDa and was purified through affinity chromatography. BALB/c mice were injected subcutaneously with the recombinant protein, VP1, VP8 and vaccines for rotavirus and hepatitis A virus, both with and without ALUM and M720 adjuvants. ELISA assays were used to measure total IgG, IgG1, IgG2, and short-term and long-term IL-5 and IFN-γ responses.
UNASSIGNED: The fusion protein, when combined with adjuvants, elicited significantly higher total IgG, IgG1, and IgG2 responses compared to VP1 and VP8 alone, as well as the rotavirus and hepatitis A vaccines. Furthermore, it induced a higher short-term IL-5 and IFN-γ response while demonstrating a higher long-term IL-5 response compared to the rotavirus and hepatitis A vaccines.
UNASSIGNED: This study demonstrates that the VP8*-rotavirus+AAY+HAV-VP1 fusion protein is a promising dual vaccine candidate for immunization against hepatitis A and rotaviruses.
■使用大肠杆菌表达系统产生VP8*-轮状病毒+AAY+HAV-VP1融合蛋白。重组蛋白的分子量约为45.5kDa,通过亲和层析纯化。BALB/c小鼠皮下注射重组蛋白,VP1,VP8和轮状病毒和甲型肝炎病毒疫苗,有和没有ALUM和M720佐剂。ELISA测定用于测量总IgG,IgG1、IgG2以及短期和长期IL-5和IFN-γ应答。
■融合蛋白,当与佐剂结合使用时,引起明显更高的总IgG,与单独的VP1和VP8相比,IgG1和IgG2应答,以及轮状病毒和甲型肝炎疫苗。此外,与轮状病毒和甲型肝炎疫苗相比,它诱导了更高的短期IL-5和IFN-γ反应,同时表现出更高的长期IL-5反应。
■这项研究表明,VP8*-轮状病毒+AAY+HAV-VP1融合蛋白是免疫甲型肝炎和轮状病毒的有希望的双重疫苗候选物。